LOX encodes a member of the lysyl oxidase family proteins, which has previously been proposed to promote epithelial to mesenchymal transition in prostate cancer (Gonzalez-Chavarria et al., 2018), and its propeptide domain may display tumor suppressor activities (Agra et al., 2013). Here, LOX is linked to neoplasm.